Description: Beijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions and consumer healthcare providers in Mainland China and internationally. It offers Airdoc-AIFUNDUS (1.0), an AI-based software as a medical device for auxiliary diagnosis of diabetic retinopathy; Airdoc-AIFUNDUS (2.0) for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration; and Airdoc-AIFUNDUS (3.0) for the auxiliary diagnosis of pathological myopia, retinal detachment, glaucoma detection, cataracts detection, ICVD/ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial, hypertension retinopathy, and anemia. The company also provides health risk assessment solutions to detect risk indicators, such as various lesions and diseases, hyperthyroidism, graves ophthalmopathy, retinal vein occlusion, dementia, Parkinson's disease, atrial fibrillation, and arteriosclerosis in a range of healthcare environments, including health checkup centers, community clinics, insurance companies, optometry centers, and pharmacies. In addition, it offers hardware devices, including fundus cameras. The company was incorporated in 2015 and is headquartered in Beijing, China.
Home Page: www.airdoc.com
Building 2
Beijing,
100089
China
Phone:
86 400 100 3999
Officers
| Name | Title |
|---|---|
| Mr. Dalei Zhang | CEO & Exec. Chairman |
| Ms. Wenting Yang | Joint Company Sec. & CFO |
| Dr. Yuzhong Chen | Exec. Director |
| Mr. Hailong Chen | Exec. Director |
| Mr. Fei Gao | Exec. Director |
| Ms. Lai Shan So C.S., CGP | Joint Company Sec. |
Exchange: HK
Country: HK : Hong Kong
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7739 |
| Price-to-Sales TTM: | 14.8656 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 340 |